Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
产品类别：
抑制剂
货号：
T40999
Product Introduction
Bioactivity
名称
NMDA receptor antagonist 2
描述
NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. It exhibits remarkable binding affinities, with an IC50 of 1.0 nM and a Ki value of 0.88 nM. This compound finds valuable application in scientific investigations focusing on neuropathic pain and Parkinson’s disease.
体外活性
NMDA receptor antagonist 2 leads to excellent potency at NR2B (K i =0.88 nM) and selectivity over hERG binding (IP=20000 nM). NMDA receptor antagonist 2 is evaluated in a functional assay measuring Ca 2+ flux in cells expressing recombinant NR1/NR2B receptors. Selectivity over the hERG-channel is evaluated in an MK-499-binding assay[1].NMDA receptor antagonist 2 is highly potent in a functional assay using cells expressing NR2B (IC 50 =1.0 nM) and remains equipotent in a binding assay using a sample of homogenized human temporal cortex (K i =0.81 nM). In an electrophysiology assay using NR2B receptors,?Compound 22?shows full blockade of ion flux with?K D =0.35 nM. Compound?22?also exhibits high levels of selectivity over NR2A (IC 50 =200 μM), hERG binding (IP=20 μM), α-adrenergic receptors based on Prazosin binding (IC 50 >100 μM),?and CYP P450s including CYP3A4, 2C9, and 2D6[1].
体内活性
In pharmacokinetic studies with higher species, NMDA receptor antagonist 2 shows excellent oral bioavailability (F=83%), half-life (T 1/2 =7.5 hours) and clearance (CL=3.6 mL/min/kg) in dog. And it exhibits moderate clearance (CL=12 mL/min/kg) and oral bioavailability (F=17%) in rhesus, the half-life (T 1/2 ) is 1.5 hours[1].
In a rat pharmacokinetic study, NMDA receptor antagonist 2 shows oral bioavailability (F=23 %), half-life (T 1/2 =0.7 hours) and clearance (CL=24 mL/min/kg), the receptor occupancy ED 50 with oral administration is 4.8 mg/kg in rat[1].
In the spinal nerve ligation model of neuropathic pain in rats, surgical ligation of two lumbar nerves in the spinal column induces a state of mechanical allodynia[1].NMDA receptor antagonist 2 (oral administration; 3-30 mg/kg) inhibits tactile allodynia in a dose-dependent manner after oral administration at 10 and 30 mg/kg. It produces an average improvement in the maximal possible effect of 15% (3 mg/kg), 41% (10 mg/kg), and 69% (30 mg/kg) compared to vehicle treated animals[1].NMDA receptor antagonist 2 (oral administration; 3-30 mg/kg) is efficacious in an acute rodent model of Parkinson’s disease. Haloperidol (HY-14538) is administered at a dose previously shown to elicit an acute cataleptic response in rats, compound 22 reduces catalepsy scores in a dose-dependent manner, producing average improvements of 34% (3 mg/kg), 86% (10 mg/kg), and 92% (30 mg/kg) when it compares to vehicle group[1].
存储条件
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
